Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement
- PMID: 24423981
- PMCID: PMC4026349
- DOI: 10.1210/er.2013-1058
Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement
Abstract
Despite the high prevalence of performance-enhancing drug (PED) use, media attention has focused almost entirely on PED use by elite athletes to illicitly gain a competitive advantage in sports, and not on the health risks of PEDs. There is a widespread misperception that PED use is safe or that adverse effects are manageable. In reality, the vast majority of PED users are not athletes but rather nonathlete weightlifters, and the adverse health effects of PED use are greatly underappreciated. This scientific statement synthesizes available information on the medical consequences of PED use, identifies gaps in knowledge, and aims to focus the attention of the medical community and policymakers on PED use as an important public health problem. PED users frequently consume highly supraphysiologic doses of PEDs, combine them with other PEDs and/or other classical drugs of abuse, and display additional associated risk factors. PED use has been linked to an increased risk of death and a wide variety of cardiovascular, psychiatric, metabolic, endocrine, neurologic, infectious, hepatic, renal, and musculoskeletal disorders. Because randomized trials cannot ethically duplicate the large doses of PEDs and the many factors associated with PED use, we need observational studies to collect valid outcome data on the health risks associated with PEDs. In addition, we need studies regarding the prevalence of PED use, the mechanisms by which PEDs exert their adverse health effects, and the interactive effects of PEDs with sports injuries and other high-risk behaviors. We also need randomized trials to assess therapeutic interventions for treating the adverse effects of PEDs, such as the anabolic-androgen steroid withdrawal syndrome. Finally, we need to raise public awareness of the serious health consequences of PEDs.
Figures
Similar articles
-
Use of growth hormone, IGF-I, and insulin for anabolic purpose: Pharmacological basis, methods of detection, and adverse effects.Mol Cell Endocrinol. 2018 Mar 15;464:65-74. doi: 10.1016/j.mce.2017.06.010. Epub 2017 Jun 9. Mol Cell Endocrinol. 2018. PMID: 28606865 Free PMC article. Review.
-
Anabolic steroid use in adolescents: identification of those at risk and strategies for prevention.Phys Sportsmed. 2010 Oct;38(3):105-13. doi: 10.3810/psm.2010.10.1815. Phys Sportsmed. 2010. PMID: 20959703 Review.
-
Performance-enhancing drugs and the Olympics.J Intern Med. 2022 Feb;291(2):181-196. doi: 10.1111/joim.13431. Epub 2022 Jan 10. J Intern Med. 2022. PMID: 35007384 Review.
-
Performance-Enhancing Drugs in Healthy Athletes: An Umbrella Review of Systematic Reviews and Meta-analyses.Sports Health. 2024 Sep-Oct;16(5):695-705. doi: 10.1177/19417381231197389. Epub 2023 Sep 9. Sports Health. 2024. PMID: 37688400 Free PMC article.
-
The Changing Drug Culture: Use and Misuse of Appearance- and Performance-Enhancing Drugs.FP Essent. 2016 Feb;441:30-43. FP Essent. 2016. PMID: 26881771 Review.
Cited by
-
Abdominal Hypertrophy Syndrome: Characteristics and Potential Pathophysiology.Cureus. 2024 Oct 21;16(10):e72026. doi: 10.7759/cureus.72026. eCollection 2024 Oct. Cureus. 2024. PMID: 39569303 Free PMC article. Review.
-
Harm reduction techniques among cisgender gay, bisexual, and queer men using anabolic androgenic steroids: a qualitative study.Harm Reduct J. 2024 Nov 11;21(1):196. doi: 10.1186/s12954-024-01121-8. Harm Reduct J. 2024. PMID: 39523302 Free PMC article.
-
Modified-release gliclazide acutely improves recovery but causes undesirable blood glucose decrease after a resistance exercise session in healthy adults: a pilot study for a randomized clinical trial.Arch Endocrinol Metab. 2024 Jul 30;68:e230381. doi: 10.20945/2359-4292-2023-0381. eCollection 2024. Arch Endocrinol Metab. 2024. PMID: 39420894 Free PMC article. Clinical Trial.
-
Nandrolone decanoate-induced hypogonadism in male rats: Dose- and time-dependent effects on pituitary and testicular hormonal functions.Physiol Rep. 2024 Oct;12(19):e70053. doi: 10.14814/phy2.70053. Physiol Rep. 2024. PMID: 39370302 Free PMC article.
-
Non-ischemia Cardiomyopathy and Polycythemia Secondary to Anabolic-Androgenic Steroid Use.Cureus. 2024 Aug 14;16(8):e66850. doi: 10.7759/cureus.66850. eCollection 2024 Aug. Cureus. 2024. PMID: 39280364 Free PMC article.
References
-
- Parkinson AB, Evans NA. Anabolic androgenic steroids: a survey of 500 users. Med Sci Sports Exerc. 2006;38(4):644–651. - PubMed
-
- Wilson JD. Androgen abuse by athletes. Endocr Rev. 1988;9(2):181–199. - PubMed
-
- Handelsman DJ. Commentary: androgens and “anabolic steroids”: the one-headed janus. Endocrinology. 2011;152(5):1752–1754. - PubMed
-
- Miner JN, Chang W, Chapman MS, et al. An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology. 2007;148(1):363–373. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical